Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 13 December 2016, 09:17 HKT/SGT
Share:
    

Source: Jacobson Pharma Corporation Limited
Jacobson Pharma Announces Acquisition of 100% Interest in Ho Chai Kung Brand
Strategic Move to Build a Proprietary Medicine Portfolio with Regional Recognition

HONG KONG, Dec 13, 2016 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines, today announces the acquisition of 100% interest in a Target Group (comprising "Karen Pharmaceutical Company Limited", "Vincents Pharma Trading Company Limited", and "Ho Chai Kung Medicine Manufactory Limited") which carries a heritage household brand, Ho Chai Kung, at a total consideration of HK$568 million. This acquisition, along with the Group's recent acquisition of Medipharma Limited back in October 2016, represents a major step forward in relation to Jacobson Pharma's strategic roadmap to reinforce their already strong position in the proprietary medicine market segment.

The catchy memorable advertising slogan "Fast pain relief within just five minutes" was a classic and signature branding campaign at the time. Above is one of Ho Chai Kung's most renowned proprietary medicines, Ho Chai Kung Tji Thung San.

The Target Group offers a wide range of branded medicines under the Ho Chai Kung franchise in the OTC channel, notable ones include Ho Chai Kung Tji Thung San and Ho Chai Kung Analgesic Tablets. The brand name of Ho Chai Kung was originated in the 1930's and has been enjoying a high brand awareness and a strong market position in the analgesics (pain-killer) category in Hong Kong, China and South-East Asia markets.

Ho Chai Kung is a well-known OTC brand that enjoys a strong market position and high brand awareness in the pain-killer segment thus offering Jacobson Pharma a viable platform to build a family of OTC products under the Ho Chai Kung brand franchise. It also opens a new set of opportunities for Jacobson Pharma to expand its geographical reach by leveraging its already strong market presence in proprietary medicines portfolio which carries brands like Po Chai Pills, Tong Tai Chung Woodlok Oil, Contractubex Scar Gel and Doan's Ointment.

Ho Chai Kung has a prestigious brand reputation and a long heritage in Hong Kong akin to Po Chai Pills. The memorable advertising slogan "Fast pain relief within just five minutes" was once a classic and signature branding campaign back in the 80's.

The Target Group recorded an unaudited net profit after taxation and extraordinary items of HK$35.9 million and HK$38.7 million for the financial year ended March 2015 and March 2016 respectively. The unaudited total assets and net assets of the Target Group as at 31 March 2016 were HK$82.1 million and HK$72.2 million respectively. Upon completion of the acquisition, the Target Companies will become a wholly-owned subsidiary of Jacobson Pharma and the financial results will be consolidated thereafter.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma said, "The acquisition of Ho Chai Kung brand reinforces Jacobson Pharma's strategy to acquire brands and businesses that provides a sound strategic fit and also complements well with the Group's product portfolios. This strategic acquisition brings together two distinctive businesses with complementary strengths, brands and cultures. It accelerates the growth momentum for our proprietary medicine business and helps create significant operational and financial synergies to the shareholders of the Group."

"The Group expects to enhance its financial profile by benefiting upon the earning visibility of the Target Group and to unlock cost synergies through consolidation of production capacities."


Contact:
Strategic Financial Relations Limited
Vicky Lee  Tel: (852) 2864 4834  Email: vicky.lee@sprg.com.hk
Angela Ng  Tel: (852) 2864 4855  Email: angela.ng@sprg.com.hk
Angel Li   Tel: (852) 2864 4859  Email: angelok.li@sprg.com.hk
Fax: (852) 2527 1196



Topic: Press release summary
Source: Jacobson Pharma Corporation Limited

Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Jacobson Pharma Corporation Limited
Nov 22, 2024 10:00 HKT/SGT
Jacobson Pharma Announces FY2025 Interim Results
Nov 25, 2022 21:21 HKT/SGT
Jacobson Pharma Announces FY2023 Interim Results
June 29, 2022 23:20 HKT/SGT
Jacobson Pharma Announces FY2022 Annual Results
June 15, 2022 19:56 HKT/SGT
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
Mar 14, 2022 19:58 HKT/SGT
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
Nov 26, 2021 19:39 HKT/SGT
Jacobson Pharma Announces FY2022 Interim Results
June 29, 2021 23:19 HKT/SGT
Jacobson Pharma Announces FY2021 Annual Results
Feb 5, 2021 16:28 HKT/SGT
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
Jan 25, 2021 17:20 HKT/SGT
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
Jan 15, 2021 23:25 HKT/SGT
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: